BioCryst Pharmaceuticals Announces Board and Compensation Changes
Ticker: BCRX · Form: 8-K · Filed: Mar 4, 2025 · CIK: 882796
Sentiment: neutral
Topics: management-change, compensation
Related Tickers: BCRX
TL;DR
BioCryst is shuffling its board and executive pay structure.
AI Summary
BioCryst Pharmaceuticals, Inc. announced on February 28, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory plans.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, and future financial performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can indicate internal shifts that may impact future performance and strategy.
Key Players & Entities
- BioCryst Pharmaceuticals, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- Durham, North Carolina (location) — Principal Executive Offices
FAQ
What specific roles have been affected by the departure of officers or directors?
The filing indicates the departure of certain officers and directors but does not specify the exact roles in this summary section.
When was the earliest event reported in this Form 8-K?
The earliest event reported is dated February 28, 2025.
What is BioCryst Pharmaceuticals' principal executive office address?
The principal executive offices are located at 4505 Emperor Blvd., Suite 200, Durham, North Carolina 27703.
What is the company's IRS Employer Identification Number?
The IRS Employer Identification Number for BioCryst Pharmaceuticals, Inc. is 62-1413174.
What type of report is this filing?
This filing is a Current Report on Form 8-K.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 4, 2025 regarding BIOCRYST PHARMACEUTICALS INC (BCRX).